BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 24331655)

  • 1. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.
    Schefter T; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Sause W; Gaffney D;
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):101-5. PubMed ID: 24331655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG
    J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
    Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
    Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
    Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
    Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
    Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
    Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity.
    Delpech Y; Haie-Meder C; Rey A; Zafrani Y; Uzan C; Gouy S; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
    Ann Surg Oncol; 2007 Nov; 14(11):3223-31. PubMed ID: 17713822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
    Zanaboni F; Grijuela B; Giudici S; Cormio G; Babilonti L; Ghezzi F; Giorda G; Scambia G; Franchi M; Lorusso M; Ditto A; Lorusso D; Raspagliesi F
    Eur J Cancer; 2013 Mar; 49(5):1065-72. PubMed ID: 23151423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
    Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
    Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
    Ferrandina G; Gambacorta A; Gallotta V; Smaniotto D; Fagotti A; Tagliaferri L; Foti E; Fanfani F; Autorino R; Scambia G; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):778-85. PubMed ID: 25585781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.